The Service of the Commission for the Protection of Competition on the 18th of October 2010 received on behalf of the company Pfizer Inc, notification of a proposed concentration according to Article 13 of the Control of Concentrations between Enterprises Law (Number 22(I)/99), concerning the acquisition of King Pharmaceuticals Inc.
Pfizer Inc is a public company and its shares are incorporated in the New York, London, Switzerland Stock Exchange and in Euronext for trade. Pfizer Inc’s main activities concentrate in the sale of pharmaceutical products and in research and development programs for new pharmaceutical products.
King Pharmaceuticals Inc. is also a public company and its shares are incorporated in the New York Stock Exchange for trade. King Pharmaceuticals Inc´s main activities concentrate in the research, development, production and distribution of pharmaceutical products and products for animal health care.